Equity Rank's fundamental strength composite scores SNY at 70.5/100 (B+, Strong), blending profitability, balance-sheet, and cash-flow quality. Over the trailing three years, free cash flow has compounded at +6.8% per year and gross margin has moved +1.4 pp. Its SAVE composite score has moved -0.1 over the past 30 days.
Equity Rank calculates fair value for SNY by blending 19 valuation methods (8–15 run per security depending on data availability), including DCF, Graham Number, Price-to-Free-Cash-Flow, EPV, Three-Stage DCF, DDM, Residual Income, and Justified Price-to-Book. Each model is weighted by historical sector accuracy and updated regularly. Informational only — not investment advice.
Sanofi ADR (SNY) is analyzed on Equity Rank using the S·A·V·E framework: Sentiment, Analyst consensus, Valuation (DCF, Graham, multiples), and Earnings quality. The consensus fair value is a blend of multiple models designed to surface potential mispricings versus current market price.
Sanofi ADR (SNY) is classified in the Drug Manufacturer sector on Equity Rank, and its valuation methods are weighted with sector-calibrated multiples.
Equity Rank provides institutional-depth valuation research on 3,000+ US equities. Data is refreshed daily and combines quantitative models with AI-driven qualitative analysis.
All Healthcare stocks with model fair values · Undervalued Healthcare stocks
Intrinsic Value Calculator · DCF Calculator · Margin of Safety Calculator
Data study: 19 valuation models across 3,091 US stocks · Compare any two stocks